Viyash Scientific logo

Viyash Scientific

VIYASH NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹11,160 Cr
Volatility
Moderate
P/E Ratio
44.72
EBITDA
₹696 Cr
Return on Equity
7.21%
Debt to Equity
0.17
Book Value
₹64
52W High
₹298
52W Low
₹178.13

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 3.87 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 3.80% over last 3 years.
  • Working capital days have increased from 71.6 days to 111 days

Growth Rate

Revenue Growth
13.96% lower than 3Y
Net Income Growth
—
Cash Flow Change
-6.35% lower than 3Y
ROE
—
ROCE
256%
EBITDA Margin (Avg.)
45.55% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 66d ago
AI opinion · based on fundamentals
Risk high

Viyash Scientific Ltd is a healthcare company with a market cap of Rs 12,252 Cr trading at a PE of 52.7x. The company has delivered exceptional TTM sales growth of 120% and TTM profit growth of 816%, though its 3-year ROE of 6% remains below average for the sector.

Bull Case 7
  • TTM revenue growth of 120% signals a significant acceleration in business momentum compared to the 3-year CAGR of 34%
  • Compounded profit growth of 816% on a TTM basis demonstrates substantial operating leverage kicking in
  • 3-year compounded sales CAGR of 34% shows consistent top-line expansion over a meaningful period
  • ROE has improved from 6% (3-year average) to 11% in the last year, indicating improving capital efficiency
  • 10-year compounded profit CAGR of 28% reflects a long-term track record of earnings growth
  • Stock has delivered 46% CAGR over 1 year and 3 years, reflecting sustained investor confidence
  • Company is expected to deliver a good upcoming quarter based on available estimates
Bear Case 8
  • PE ratio of 52.7x is expensive and leaves limited margin of safety if growth slows
  • 3-year ROE of only 6% is well below what investors typically expect from a quality healthcare compounder
  • Working capital days have deteriorated sharply from 70.3 days to 111 days, signaling potential cash conversion issues
  • Price-to-book of 4.07x is elevated, meaning investors are paying a significant premium over net asset value
  • Despite reporting repeated profits, the company pays negligible dividends (yield of only 0.18%), retaining capital without delivering proportionate ROE
  • 5-year ROE average of just 4% suggests historically poor returns on retained earnings
  • 5-year compounded profit CAGR of only 15% contrasts starkly with TTM figures, raising questions about sustainability of recent profit surge
  • 5-year stock CAGR of 0% prior to the recent rally indicates prolonged periods of value destruction for long-term holders

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 59d ago
Headwinds 2
  • SEBI warning on SDD gaps Jul 8

    SEBI issued an administrative warning to Viyash Scientific for SDD maintenance gaps from June to October 2024, citing incomplete information in the digital database.

  • Carlyle may sell 10% stake Jun 22

    Promoter Carlyle (holding 61.3%) may offload up to 10% stake per CNBC TV18. No timeline or pricing disclosed, creating potential supply overhang.

Positives 2
  • Two new directors appointed Jun 29

    Viyash appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive Directors. Shareholders also approved a performance incentive for WTD Mr. Rajaram Narayanan.

  • Top 10 global animal health target Jun 25

    At Investor Day 2026, Viyash outlined its strategy to become a top 10 global animal health player by 2030, highlighting its integrated animal and human health platform.

Neutral 2
  • AGM set for August 11 Jul 15

    Viyash Scientific will hold its 41st AGM via video conference on August 11, 2026. Remote e-voting opens August 7.

  • Investor Day hosted June 25 Jun 17

    Viyash hosted its Investor Day 2026 on June 25 in Mumbai for analysts and institutional investors.

TL;DR: Viyash Scientific is positioning itself as a top 10 global animal health company by 2030 with board strengthening and a clear strategic roadmap. Key risks include a SEBI administrative warning on compliance gaps and potential supply overhang from Carlyle's possible 10% stake sale. Governance is tightening with new director appointments and incentive approvals. The trend is cautiously positive on strategy but near-term overhang from promoter selling and regulatory scrutiny warrants monitoring.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
333
346
329
361
390
369
774
402
792
850
858
920
946
Expenses
341
331
307
329
348
330
674
355
673
677
683
736
768
Operating Profit
-8
15
22
32
42
39
100
46
119
173
176
184
178
OPM %
-2.5%
4.4%
7%
9%
11%
11%
13%
12%
15%
20%
20%
20%
19%
Other Income
-23
10
7
-1
3
0
4
1
6
6
-27
16
8
Interest
10
13
13
12
16
14
21
15
20
18
17
15
13
Depreciation
14
15
15
16
16
17
58
16
56
59
59
60
62
PBT
-56
-3
1
3
12
8
24
16
48
102
73
125
112
Tax %
-38%
123%
-617%
52%
24%
20%
-71%
36%
24%
29%
34%
47%
29%
Net Profit
-35
-7
11
1
9
6
42
10
37
73
49
66
79
EPS in Rs
-1.4
-0.34
0.33
-0.04
0.26
0.1
1.78
0.37
1.27
2.18
0.88
1.19
1.51
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
443
606
684
848
1,039
1,179
1,362
1,413
1,421
1,370
3,007
3,420
3,575
Expenses
425
550
641
765
914
1,009
1,150
1,303
1,409
1,308
2,620
2,768
2,864
Operating Profit
18
56
43
83
125
170
212
109
12
61
387
653
711
OPM %
4.2%
9%
6%
10%
12%
14%
16%
8%
0.8%
4.5%
13%
19%
20%
Other Income
48
14
9
436
9
10
0
11
-58
-6
-49
-1
3
Interest
43
38
28
33
33
36
24
16
36
48
86
69
61
Depreciation
32
46
40
41
42
51
51
52
56
62
239
234
240
PBT
-8
-14
-17
444
59
94
137
53
-138
-55
13
349
413
Tax %
40%
19%
-3%
3%
3%
13%
24%
15%
-11%
-46%
-20%
36%
—
Net Profit
-12
-16
-16
431
57
82
104
45
-122
-30
16
225
267
EPS in Rs
-0.7
-0.78
-0.57
17.3
1.97
2.81
3.84
1.65
-4.86
-1.44
0.93
4.06
5.76
Div. Payout %
0%
0%
0%
1%
10%
0%
13%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
30
48
49
49
49
50
50
50
50
50
50
87
Reserves
61
898
928
599
657
637
678
642
649
607
2,382
2,824
Borrowings
473
312
416
305
325
343
277
365
444
488
654
490
Other Liabilities
343
265
503
380
346
424
381
378
374
389
1,042
1,195
Total Liabilities
908
1,523
1,896
1,332
1,378
1,454
1,386
1,435
1,517
1,534
4,128
4,596
Fixed Assets
474
586
684
476
498
577
536
564
605
592
2,103
2,103
CWIP
39
24
33
18
23
13
31
12
55
16
43
70
Investments
59
428
428
239
180
171
83
38
0
4
0
0
Other Assets
336
485
751
599
677
693
737
821
856
922
1,981
2,422
Total Assets
908
1,523
1,896
1,332
1,378
1,454
1,386
1,435
1,517
1,534
4,128
4,596
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-24
0
-7
45
116
115
115
31
17
31
345
323
Investing
-157
-310
-116
7
-68
-72
10
-94
-65
-6
-448
-84
Financing
179
309
147
-57
-20
-43
-139
67
32
-1
87
-123
Net Cash Flow
-1
-2
24
-5
28
0
-14
4
-16
23
-16
115
Free Cash Flow
-137
-63
-82
0
92
75
70
-1
-58
19
258
225
CFO/OP
-143
-3
5
65
92
75
75
52
263
73
102
59
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
95
116
136
111
98
99
93
85
88
89
98
112
Inventory Days
153
164
165
125
134
132
139
160
152
166
169
188
Days Payable
147
175
208
127
141
133
119
119
107
121
121
140
Cash Conversion Cycle
101
105
93
110
92
98
112
126
132
135
146
160
Working Capital Days
-111
65
-25
20
33
29
51
54
46
30
74
111
ROCE %
8%
2%
1%
40%
9%
12%
16%
6%
-3%
0%
8%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Viyash Scientific insights

65 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Shareholding Pattern

DIIs3.75%Promot.61.31%FIIs4.50%Others9.91%Public20.52%As ofJun 2026

Documents

Frequently Asked Questions about Viyash Scientific

What does Viyash Scientific Ltd do?
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutica...
Where is Viyash Scientific Ltd (VIYASH) listed?
Viyash Scientific Ltd trades as VIYASH on the NSE and under code 512529 on the BSE.
Which sector does Viyash Scientific Ltd belong to?
Viyash Scientific Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Viyash Scientific Ltd?
Viyash Scientific Ltd has a market capitalisation of ₹11,160 Cr, which places it in the Mid Cap band.
What is the PE ratio of Viyash Scientific Ltd?
Viyash Scientific Ltd trades at a PE ratio of 44.72, against a book value of ₹64 per share.
What is the 52-week high and low of Viyash Scientific Ltd?
Over the last 52 weeks Viyash Scientific Ltd has traded between ₹178.13 and ₹298.
Does Viyash Scientific Ltd pay dividends?
Viyash Scientific Ltd has a dividend yield of 0.19%.
What is the Return on Equity (ROE) of Viyash Scientific Ltd?
Viyash Scientific Ltd reported a return on equity of 7.21%. Its debt-to-equity ratio is 0.17.

Company Information

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

Website sequent.in
Listed 2016-03-10
Face Value ₹ 2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIYASH.md for Viyash Scientific Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List